1. Home
  2. Directory
  3. Pennsylvania
  4. Philadelphia
  5. Student In An Organized Health Care Education Training Program
  6. NPI Profile
  7. Prescriptions 1619322716

REKA ZSILINSZKA
Prescription History 1619322716
Student in an Organized Health Care Education/Training Program in Philadelphia, PA

NPI Status: Active since April 27, 2016

Contact Information

3400 SPRUCE ST
HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA
PHILADELPHIA, PA
ZIP 19104
Phone: (215) 662-6305

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for REKA ZSILINSZKA, an active Student in an Organized Health Care Education/Training Program specialist practicing in Philadelphia, PA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 75 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydrocodone-Acetaminophen, which accounts for 33 claims alone.

Medication Index

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 91
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills24.9
Peer Average Days Supply225
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $180.18 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.02

State Avg Cost Per Claim

$12.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Cephalexin

Generic Formulation: CephalexinSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 100
PA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply272
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 51.9% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $139.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.73

State Avg Cost Per Claim

$8.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 95
PA State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills61.5
Peer Average Days Supply1,282
Conservative Utilization

This provider writes prescriptions for this formulation 45.9% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $226.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.86

State Avg Cost Per Claim

$21.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Emergency Medicine
Provider Metrics Summary
Total Claims 17
30-Day Fills 17.0
Days Supply 51
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply235
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $118.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.95

State Avg Cost Per Claim

$22.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like REKA ZSILINSZKA provides transparency into local medical care patterns within Philadelphia, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.